Sellas Life Sciences is trading 4.9% higher at $14.44 as the stock rebounds from recent volatility despite a lack of fresh company-specific catalysts.
- The upward move appears aligned with a broadly positive U.S. equity session, with major indices gaining between 0.8% and 1%.
- The price action follows a period of heavy trading and sharp momentum swings observed over the past two weeks.
- No new clinical trial updates, regulatory filings, or major analyst actions have been reported for the company as of July 9, 2026.